Medicare Advantage Can Limit Your Cancer Care When Choices Matter Most

A Medicare plan can look excellent when the biggest healthcare decision is which primary-care doctor to visit. Cancer changes the calculation.

A prostate cancer diagnosis can present several reasonable treatment paths, including active surveillance, surgery, external-beam radiation, brachytherapy, hormone therapy and, in more advanced cases, additional drug treatments. The appropriate choice depends on the cancer’s stage and risk level, the patient’s age and health, expected side effects, and the experience of the physicians treating the disease. Original Medicare and Medicare Advantage are both required to cover medically necessary Medicare benefits, but they do not necessarily provide the same practical access to physicians, hospitals and treatment technologies. Medicare Advantage plans can require prior authorization, use provider networks and apply utilization-management rules that create another layer between the physician’s recommendation and the care the patient ultimately receives.

That distinction becomes especially important when a patient wants treatment at a major cancer center or is considering a costly technology such as proton therapy. The issue is not that Medicare Advantage categorically refuses cancer treatment, nor that Original Medicare automatically approves every treatment a physician recommends. The more accurate concern is that a Medicare Advantage enrollee can encounter restrictions that a patient in Original Medicare may not face in the same way, and those restrictions can become painfully important after a serious diagnosis.

A Prostate Cancer Diagnosis Can Produce Several Reasonable Choices

Prostate cancer illustrates the issue particularly well because there is rarely one treatment that is automatically best for every patient. Depending on the characteristics of the tumor, options can include active surveillance, radical prostatectomy, conventional external-beam radiation, stereotactic radiation, brachytherapy and combinations of radiation and hormone therapy. The National Cancer Institute notes that treatment decisions involve tradeoffs because surgery and radiation can both control disease while producing different patterns of urinary, sexual and bowel side effects.

That means access matters beyond simply receiving “cancer treatment.” A patient may want a surgeon who performs a large number of robotic prostatectomies, a radiation oncologist specializing in prostate disease or a multidisciplinary team that can compare surgery with several radiation approaches. Someone with complicated or recurrent disease may seek evaluation at a nationally recognized cancer center rather than relying on the nearest hospital. The value of insurance in that situation is not merely whether it pays something toward treatment, but how easily the patient can reach the clinicians best equipped to discuss the options.

Original Medicare generally allows beneficiaries to use any physician or hospital that accepts Medicare, without the conventional HMO or PPO network used by Medicare Advantage. Medicare Advantage plans may require nonemergency care to remain within the plan’s service area and provider network, with some PPOs allowing out-of-network care at higher cost and many HMOs providing little routine out-of-network coverage. For routine care, that distinction may seem minor. For a cancer patient who wants a particular specialist or institution, it can suddenly become one of the most important features of the insurance.

Proton Therapy Shows Why “Covered” and “Accessible” Are Different Questions

Proton therapy is a form of external-beam radiation that uses positively charged particles rather than conventional photons. Its physical advantage is that protons can deposit much of their radiation dose at a planned depth and then stop, potentially reducing the amount of radiation delivered beyond the tumor. That characteristic can be particularly useful when tumors sit near sensitive tissues, although whether the dosimetric advantage produces meaningfully better patient outcomes depends on the cancer and the individual case.

For prostate cancer, proton therapy should not be described as universally superior to modern photon radiation. Recent randomized evidence presented in 2024 found that proton therapy and intensity-modulated photon therapy produced similarly strong disease control and quality-of-life outcomes for localized prostate cancer, reinforcing that both can be excellent options. Earlier reviews likewise found mixed comparative evidence and emphasized that the theoretical ability to reduce radiation exposure does not automatically translate into better outcomes for every prostate patient.

That does not mean proton therapy has no clinical value. A radiation oncologist may believe it offers an advantage for a particular patient because of anatomy, previous radiation exposure or the need to reduce dose to nearby structures. Medicare covers radiation therapy when coverage requirements are met, including outpatient radiation under Part B. The practical problem can arise when a Medicare Advantage plan requires prior authorization or when the proton center recommended by the physician is outside the plan’s network.

The patient may therefore confront a frustrating situation in which cancer treatment is broadly covered, but the specific treatment or facility the physician prefers requires another approval or is difficult to access under the plan. That is a very different problem from having no cancer coverage at all, but it can matter enormously to the person sitting in the oncologist’s office.

Prior Authorization Is Where Medicare Advantage Can Add Friction

Medicare Advantage plans are allowed to use prior authorization for certain services, although they must ultimately provide the medically necessary benefits covered by Medicare and comply with federal coverage standards. Prior authorization requires the physician or facility to obtain the insurer’s approval before specified treatment, imaging, rehabilitation or other care proceeds. The process is intended partly to control unnecessary utilization, but federal oversight has repeatedly identified instances in which beneficiaries faced inappropriate denials or avoidable delays.

A major 2022 investigation by the Department of Health and Human Services Office of Inspector General reviewed denied Medicare Advantage requests and found that 13% of the prior-authorization denials examined met Medicare coverage rules and likely would have been approved under Original Medicare. The cases included advanced imaging and post-acute care, with some denials resulting from plans applying internal clinical criteria beyond the relevant Medicare coverage requirements or determining that documentation was insufficient when the OIG’s physician reviewers believed the records supported medical necessity.

That 13% figure should not be interpreted to mean that 13% of all Medicare Advantage medical care is improperly denied. It applies to the sample of denied requests examined by the OIG. It is nevertheless significant because cancer treatment frequently depends on precisely the kinds of services that can be subject to utilization review: advanced imaging, sophisticated radiation, expensive drugs, hospital procedures and rehabilitation after treatment.

CMS has continued responding to these concerns with new rules intended to make prior authorization more transparent and timely. The agency’s interoperability and prior-authorization requirements are designed to improve information exchange and reduce administrative burden, while Medicare Advantage policy changes have increasingly restricted the use of internal coverage criteria that unnecessarily limit access. The reforms may improve the system, but they do not eliminate the need for patients to understand how their individual plan handles cancer care.

Appeals Work Surprisingly Often, but Patients Have to Use Them

A denied request is not necessarily the end of the treatment discussion. Medicare Advantage beneficiaries have formal appeal rights, and the physician can often provide additional records or explain why a treatment is medically necessary. Standard and expedited processes are available depending on the urgency of the situation, and unresolved cases can eventually reach an independent review entity rather than remaining solely with the insurer.

The striking problem is how often initial denials change after someone challenges them. CMS has reported that Medicare Advantage plans overturn about 80% of their claim-denial decisions when those denials are appealed to the plan, while also noting that only a small percentage of denied claims are appealed. A 2026 OIG investigation focusing specifically on skilled-nursing-facility admissions found an even higher reversal rate: Medicare Advantage organizations overturned 95% of appealed SNF denials in the study, while beneficiaries and providers appealed only 18% of the original denials.

Those figures do not mean every cancer-treatment appeal has an 80% or 95% chance of success, because the underlying studies encompass different categories of decisions. They do reveal something important about the system: An initial denial can be wrong or reconsidered, and patients who accept it without challenge may lose access to care that could have been approved.

The difficulty is that appeals require time and persistence during a period when patients are already overwhelmed. Medical records must be gathered, physicians may need to speak with reviewers and expedited procedures may need to be requested when waiting could jeopardize health. Cancer patients should therefore involve their oncology office early, because large cancer programs often employ financial counselors or authorization specialists familiar with the appeal process.

Cancer Networks Can Matter as Much as Cancer Benefits

Medicare Advantage plans often compete on premium, dental benefits, vision coverage and other easily understood features. A cancer network is harder to evaluate before someone actually needs it.

Medicare’s own comparison tool warns that Medicare Advantage beneficiaries may need to use doctors and other providers within their plan’s network and service area for nonemergency treatment. Original Medicare generally provides broader nationwide access to participating Medicare providers. That difference can be particularly important in oncology because complex cancers may benefit from evaluation at specialized institutions whose physicians see large numbers of similar cases.

A plan can have an adequate oncology network while still excluding the particular cancer center a patient wants to use. CMS recognizes a group of specialized cancer hospitals, including institutions such as MD Anderson Cancer Center and Fox Chase Cancer Center, but whether a particular Medicare Advantage plan contracts with a particular hospital is a separate question. Medicare beneficiaries should never assume that a famous institution accepts every Medicare Advantage plan simply because it accepts Original Medicare.

This is also why the phrase “my doctor takes Medicare” can be misleading. A specialist may accept Original Medicare but not participate in a particular Medicare Advantage network. The relevant question is whether the physician and facility are in-network for the exact plan, and ideally whether the network status has been confirmed with both the insurer and the provider.

Imaging and Biomarker Testing Can Affect the Treatment Before It Begins

Modern cancer care increasingly depends on diagnostic information obtained before treatment is selected. Prostate cancer patients may undergo MRI, CT imaging, PET scans or molecular testing depending on their disease characteristics. Advanced cancer treatment across multiple tumor types can also involve genomic testing that identifies mutations or biomarkers capable of influencing drug selection.

Original Medicare Part B covers medically necessary diagnostic laboratory testing when ordered by a healthcare provider, and CMS maintains national coverage for certain next-generation sequencing tests for qualifying patients with advanced cancer. Medicare Advantage plans must provide the underlying Medicare-covered benefits but can use authorization procedures consistent with federal rules.

The danger of delay is not that every authorization request materially worsens cancer outcomes. Cancer biology and urgency vary enormously. The concern is that diagnostic delays can postpone the point at which physicians have enough information to determine the appropriate treatment, while creating additional anxiety for someone who has recently learned that cancer may be present.

Patients should ask about authorization requirements before scheduling major imaging or molecular tests, particularly when physicians want them completed at an outside center. That gives the oncology office time to obtain approval and reduces the chance that the patient discovers after the test that the facility or service was outside plan rules.

Cancer Drugs Create Another Layer of Insurance Complexity

Cancer medication does not fit neatly into one Medicare benefit. Drugs administered by a physician or in an outpatient clinical setting can fall under Medicare Part B, while many medications taken by the patient at home are covered through Part D. Advanced prostate cancer alone can involve injected, infused and oral therapies across different stages of disease, which means the coverage pathway can change as treatment changes.

Medicare Advantage plans that include drug coverage can apply formulary rules and utilization-management requirements to Part D medications, while Part B drugs may also be subject to plan coverage procedures. CMS has continued developing oncology payment models specifically because cancer drug treatment represents a major area of Medicare spending and clinical complexity.

A patient should therefore ask more than whether the plan “covers cancer drugs.” The important questions are whether the exact medication is covered, what authorization criteria apply, whether step therapy is permitted, what the cost sharing will be and whether the oncologist’s infusion center participates in the plan.

The answer can change over the course of treatment. A medication that is irrelevant at diagnosis may become essential after recurrence or progression, which is another reason a cancer diagnosis can expose limitations that were invisible when the Medicare plan was originally selected.

Clinical Trials Are Covered Differently Than Many Patients Expect

Clinical trials can become important for patients with advanced disease, particularly when standard treatments have stopped working or researchers are testing a promising new approach. Medicare covers certain routine patient costs associated with qualifying clinical research studies, including some office visits and tests.

Medicare Advantage beneficiaries do not necessarily lose that protection. The 2026 Medicare handbook explains that when an Advantage enrollee participates in certain clinical research studies, Original Medicare may pay some costs along with the Medicare Advantage plan, and beneficiaries should contact the plan to determine how coverage is coordinated.

Access can still be complicated when the physicians or research center conducting the trial sit outside the plan’s ordinary network. The experimental treatment itself may also be paid by the study sponsor rather than Medicare, while unrelated or noncovered services can remain the patient’s responsibility. Anyone considering a clinical trial should ask the research center to review insurance arrangements before enrollment instead of assuming either that Medicare pays everything or that Medicare Advantage prevents participation entirely.

Rehabilitation Can Become the Next Prior-Authorization Battle

Cancer treatment does not end when surgery, radiation or chemotherapy ends. Some patients need rehabilitation, home healthcare or skilled nursing care before they can safely return to ordinary life. Those post-acute services can become another point at which network restrictions and prior authorization matter.

The OIG’s 2026 skilled-nursing investigation is especially relevant because it found that the 19 Medicare Advantage organizations studied denied 12% of SNF admission requests during the month examined, and 95% of the denials that were appealed were ultimately overturned in favor of the enrollee. The report was not limited to cancer patients, but it illustrates how an authorization decision made after a hospitalization can affect access to medically necessary recovery care.

For someone recovering from major cancer surgery, the practical issue may be whether the preferred rehabilitation facility is in-network, how quickly authorization is granted and what happens if the initial number of approved days is exhausted. Families should ask these questions before discharge when possible, because fighting about coverage after a patient is medically ready to leave the hospital creates additional pressure.

The cancer plan should therefore include recovery, not only tumor treatment. A policy that provides excellent access to the surgeon but severely limits post-acute options may still create significant problems once treatment is complete.

Original Medicare Has Tradeoffs Too

The disadvantages of Medicare Advantage should not be turned into an unrealistic picture of Original Medicare. Original Medicare generally gives beneficiaries broader provider access and avoids many conventional plan-network restrictions, but it also leaves substantial cost sharing unless the beneficiary has Medigap or another form of supplemental coverage.

Under Original Medicare, Part B typically leaves the beneficiary responsible for 20% of the Medicare-approved amount after the deductible, and there is no broad annual out-of-pocket maximum for Parts A and B without supplemental coverage. Extensive cancer treatment could therefore create serious costs for someone using Original Medicare alone.

Medicare Advantage provides a yearly out-of-pocket maximum for covered Part A and Part B services and can offer additional benefits, making it a reasonable choice for many beneficiaries. The relevant comparison for someone worried about future cancer care is often Medicare Advantage versus Original Medicare with appropriate Medigap and Part D coverage, not Advantage versus completely uninsured gaps in Original Medicare.

The best choice depends on premiums, local networks, finances and health priorities. The danger is selecting coverage only because one plan costs less during a healthy year without examining what happens after a major diagnosis.

Ask the Cancer Questions Before You Have Cancer

Nobody can predict which disease will appear later in life, but Medicare beneficiaries can evaluate whether their coverage provides meaningful flexibility before a diagnosis makes the question urgent. A plan comparison should include the doctors and hospitals someone would want if a serious illness developed, not merely the physicians used today.

For Medicare Advantage, beneficiaries should determine which major regional cancer centers participate in the network, whether out-of-network specialty care is available, which services routinely require authorization and what the maximum annual medical exposure could be. They should also understand the appeal process and whether the plan provides case managers who help coordinate complex treatment.

For Original Medicare with Medigap, the questions are different: whether desired specialists accept Medicare, what the supplement covers, how prescription drugs are handled and whether the combined premiums remain affordable as the beneficiary ages. The broader provider access may be valuable, but it comes with a recurring premium cost that Medicare Advantage enrollees may have avoided.

These decisions become particularly important because switching from Medicare Advantage back to Original Medicare does not automatically guarantee that someone can obtain the Medigap policy they want. Outside protected enrollment or guaranteed-issue situations, medical underwriting may apply in many states. Waiting until after a cancer diagnosis to decide broader access is desirable can therefore be far more complicated than making that assessment while healthy.

Cancer Changes What “Good Insurance” Means

The prostate-cancer example reveals the central problem with evaluating Medicare coverage based primarily on monthly premiums and supplemental perks. A $0-premium Medicare Advantage plan can be an excellent value for one person and a frustrating limitation for another, depending on which physicians, hospitals and treatments become necessary.

Medicare Advantage plans must cover the medically necessary services that Original Medicare covers. The difference is in how access can be managed through networks, prior authorization and plan rules. Federal regulators have repeatedly found enough problems with denied requests to strengthen oversight, including the OIG’s finding that 13% of sampled denied prior-authorization requests met Medicare coverage requirements and CMS’s acknowledgement that a large majority of appealed claim denials are overturned.

That should not scare every beneficiary away from Medicare Advantage. It should change the questions asked before enrollment. Which cancer centers are available? Will the plan cover out-of-network specialists? Which scans and treatments require prior authorization? How quickly are urgent requests processed? What is the procedure if the oncologist believes the plan denied the best treatment?

Cancer treatment is rarely just a question of whether insurance pays for “cancer.” It is a sequence of decisions about doctors, diagnostics, surgery, radiation, medication, rehabilitation and sometimes clinical trials. The more complicated that sequence becomes, the more valuable flexibility can become.

The best time to find out how much flexibility a Medicare plan provides is before the day a physician says the word cancer.